Monday, 16 Sep 2019

You are here

Febuxostat Safe in Gout with Moderate-Severe Renal Impairment

Renal impairment is a risk factor for gout and a barrier to optimal gout management. Many of the drugs used to treat gout require adjustment in those with renal disease.

The product label for febuxostat states that "no dose adjustment is necessary in patients with mild or moderate renal impairment (Clcr 30 to 89 mL/min) and that there are insufficient data on patients with severe renal impairment (Clcr less than 30 mL/min). Hence, caution is advised for such patients.

Renal adverse events reported with febuxostat include hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, urgency, incontinence, an tubulointerstitial nephritis.

The safety and efficacy of febuxostat in patients with moderate to severe renal impairment (GFR ≥ 15 to < 50 mL/min) are limited. Saag and colleagues have studied 96 subjects with moderate to severe renal impairment and gout over a 12 month period in a randomized, double-blind, placebo-controlled study using febuxostat 30 mg BID, febuxostat 40/80 mg QD, or placebo.

After 12 month, the change from baseline in serum creatinine was the same in either febuxostat group compared to placebo. However the number with with sUA < 6.0 mg/dL was significantly greater in both febuxostat groups compared to placebo.

Thus, febuxostat is effective and well tolerated in gout subjects with moderate to severe renal impairment. While monitoring is still advised, no initial dose adjustments are necessary. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Modifiable Risk Factors for Hyperuricemia

Choi and colleagues have shown that four modifiable risk factors (BMI, the DASH diet, alcohol use, and diuretic use) could individually account for a notable proportion of observed hyperuricemia. 

Researchers examine modifiable risk factors for hyperuricemia and how this could be prevented through risk factor modification in the general population.

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Allopurinol Fails to Curtail Hypertension

A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.